Recent VRPX News
- Virpax Pharmaceuticals Reports 2023 Year-End Results • Business Wire • 03/26/2024 11:30:00 AM
- Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price • Business Wire • 02/27/2024 12:31:00 PM
- Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. • Business Wire • 02/27/2024 12:30:00 PM
- Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research • Business Wire • 02/07/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:26:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:25:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:25:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:24:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:23:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:23:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:22:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:21:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 12:30:32 PM
- Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting • Business Wire • 12/29/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 01:30:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/07/2023 02:08:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 01:58:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/07/2023 01:50:05 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/21/2023 09:57:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 12:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 12:15:12 PM
- Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing • Business Wire • 11/17/2023 12:10:00 PM
- Virpax Pharmaceuticals Announces Leadership Transition • Business Wire • 11/17/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:51:23 PM
- Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments • Business Wire • 11/15/2023 09:15:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM